Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q2 2015 (← Previous) (Next →)

Filing Date: Jul 15, 2015

Total Value: $78.84B (100.0% shares, 0.0% debt)

Holdings (5)

— Clovis Oncology, Inc. 45.4%

Value $35.8B Shares 407,416 Est. Cost $56000.00 Unrealized —

— Five Prime Therapeutics, Inc. 34.4%

Value $27.13B Shares 1,092,152 Est. Cost $27000.00 Unrealized —

— Achaogen, Inc. 9.8%

Value $7.725B Shares 1,281,152 Est. Cost $13050.00 Unrealized —

— Biotie Therapies Corp. 6.8%

Value $5.365B Shares 268,672 Est. Cost $19970.00 Unrealized —

— CymaBay Therapeutics, Inc. 3.6%

Value $2.821B Shares 1,048,601 Est. Cost $9830.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	Clovis Oncology, Inc.	407,416	$35.8B	45.4%	$56000.00	—	Common Stock	189464100
—	Five Prime Therapeutics, Inc.	1,092,152	$27.13B	34.4%	$27000.00	—	Common Stock	33830X104
—	Achaogen, Inc.	1,281,152	$7.725B	9.8%	$13050.00	—	Common Stock	004449104
—	Biotie Therapies Corp.	268,672	$5.365B	6.8%	$19970.00	—	ADS	09074D103
—	CymaBay Therapeutics, Inc.	1,048,601	$2.821B	3.6%	$9830.00	—	Common Stock	23257D103